Review



leukemic cell lines kg1a  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC leukemic cell lines kg1a
    GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC ( A ), BIOCARTA_MAPK ( B ), and BIOCARTA_MTOR ( C ) pathways in MDS patient CD34 + bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: <t>KG1a</t> cells ( G ) and MDS-L ( H ). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).
    Leukemic Cell Lines Kg1a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 675 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/leukemic cell lines kg1a/product/ATCC
    Average 96 stars, based on 675 article reviews
    leukemic cell lines kg1a - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm"

    Article Title: Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm

    Journal: Leukemia

    doi: 10.1038/s41375-025-02537-2

    GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC ( A ), BIOCARTA_MAPK ( B ), and BIOCARTA_MTOR ( C ) pathways in MDS patient CD34 + bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: KG1a cells ( G ) and MDS-L ( H ). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).
    Figure Legend Snippet: GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC ( A ), BIOCARTA_MAPK ( B ), and BIOCARTA_MTOR ( C ) pathways in MDS patient CD34 + bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: KG1a cells ( G ) and MDS-L ( H ). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).

    Techniques Used: Expressing, Alamar Blue Assay, Staining



    Similar Products

    leukemic cell lines kg1a  (ATCC)
    96
    ATCC leukemic cell lines kg1a
    GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC ( A ), BIOCARTA_MAPK ( B ), and BIOCARTA_MTOR ( C ) pathways in MDS patient CD34 + bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: <t>KG1a</t> cells ( G ) and MDS-L ( H ). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).
    Leukemic Cell Lines Kg1a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/leukemic cell lines kg1a/product/ATCC
    Average 96 stars, based on 1 article reviews
    leukemic cell lines kg1a - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    human leukemic cell lines kg1a  (ATCC)
    96
    ATCC human leukemic cell lines kg1a
    GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC ( A ), BIOCARTA_MAPK ( B ), and BIOCARTA_MTOR ( C ) pathways in MDS patient CD34 + bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: <t>KG1a</t> cells ( G ) and MDS-L ( H ). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).
    Human Leukemic Cell Lines Kg1a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human leukemic cell lines kg1a/product/ATCC
    Average 96 stars, based on 1 article reviews
    human leukemic cell lines kg1a - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    leukemic cell lines kg1a  (DSMZ)
    96
    DSMZ leukemic cell lines kg1a
    Cytotoxic effect of Andosan on leukemia cell lines. Mean: mean of five experiments; SE: standard error. Comparison of the means of control with means of cells cultured with Andosan 10% showed a statistically significant difference ( p = 0.02).
    Leukemic Cell Lines Kg1a, supplied by DSMZ, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/leukemic cell lines kg1a/product/DSMZ
    Average 96 stars, based on 1 article reviews
    leukemic cell lines kg1a - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    kg1a leukemic cell line kg1a  (ATCC)
    96
    ATCC kg1a leukemic cell line kg1a
    Cytotoxic effect of Andosan on leukemia cell lines. Mean: mean of five experiments; SE: standard error. Comparison of the means of control with means of cells cultured with Andosan 10% showed a statistically significant difference ( p = 0.02).
    Kg1a Leukemic Cell Line Kg1a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kg1a leukemic cell line kg1a/product/ATCC
    Average 96 stars, based on 1 article reviews
    kg1a leukemic cell line kg1a - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    myeloid leukemic kg1a cell line  (ATCC)
    96
    ATCC myeloid leukemic kg1a cell line
    Cytotoxic effect of Andosan on leukemia cell lines. Mean: mean of five experiments; SE: standard error. Comparison of the means of control with means of cells cultured with Andosan 10% showed a statistically significant difference ( p = 0.02).
    Myeloid Leukemic Kg1a Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/myeloid leukemic kg1a cell line/product/ATCC
    Average 96 stars, based on 1 article reviews
    myeloid leukemic kg1a cell line - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    treatment human leukemic cell lines kg1a  (DSMZ)
    93
    DSMZ treatment human leukemic cell lines kg1a
    Cytotoxic effect of Andosan on leukemia cell lines. Mean: mean of five experiments; SE: standard error. Comparison of the means of control with means of cells cultured with Andosan 10% showed a statistically significant difference ( p = 0.02).
    Treatment Human Leukemic Cell Lines Kg1a, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/treatment human leukemic cell lines kg1a/product/DSMZ
    Average 93 stars, based on 1 article reviews
    treatment human leukemic cell lines kg1a - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    acute myeloid leukemic kg1a cell line  (ATCC)
    96
    ATCC acute myeloid leukemic kg1a cell line
    Cytotoxic effect of Andosan on leukemia cell lines. Mean: mean of five experiments; SE: standard error. Comparison of the means of control with means of cells cultured with Andosan 10% showed a statistically significant difference ( p = 0.02).
    Acute Myeloid Leukemic Kg1a Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acute myeloid leukemic kg1a cell line/product/ATCC
    Average 96 stars, based on 1 article reviews
    acute myeloid leukemic kg1a cell line - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC ( A ), BIOCARTA_MAPK ( B ), and BIOCARTA_MTOR ( C ) pathways in MDS patient CD34 + bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: KG1a cells ( G ) and MDS-L ( H ). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).

    Journal: Leukemia

    Article Title: Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm

    doi: 10.1038/s41375-025-02537-2

    Figure Lengend Snippet: GSEA enrichment plots based on miR-143 or miR-145 expression for the BIOCARTA_GLEEVEC ( A ), BIOCARTA_MAPK ( B ), and BIOCARTA_MTOR ( C ) pathways in MDS patient CD34 + bone marrow cells. D Imatinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. E Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with imatinib, LEN or vehicle (DMSO). F Colony output of LEN-resistant and WT MDS-L cells in the presence of imatinib (10 μM), LEN (1 μM) or vehicle (DMSO). Effect of inhibitors of pathways downstream of IGF-1R including everolimus (mTOR inhibitor, 0.1 μM), temsirolimus (mTOR inhibitor, 0.5 μM) and trametinib (MEK1/2 inhibitor, 0.03 μM) or LEN (1 μM) or vehicle (DMSO), on del(5q) cell lines: KG1a cells ( G ) and MDS-L ( H ). I Trametinib dose-response curves for LEN-resistant and WT MDS-L cells following treatment for 48 h, as measured by AlamarBlue assay. J Proportion of apoptotic cells as measured by Annexin V staining for LEN-resistant and WT MDS-L cells following 144 h treatment with trametinib (0.03 μM), LEN (1 μM) or vehicle (DMSO).

    Article Snippet: The leukemic cell lines KG1a, KG1, UT7, K562, U937, and THP1 were purchased from the American Type Culture Collection.

    Techniques: Expressing, Alamar Blue Assay, Staining

    Cytotoxic effect of Andosan on leukemia cell lines. Mean: mean of five experiments; SE: standard error. Comparison of the means of control with means of cells cultured with Andosan 10% showed a statistically significant difference ( p = 0.02).

    Journal: BioMed Research International

    Article Title: Cytotoxic Effect on Human Myeloma Cells and Leukemic Cells by the Agaricus blazei Murill Based Mushroom Extract, Andosan™

    doi: 10.1155/2017/2059825

    Figure Lengend Snippet: Cytotoxic effect of Andosan on leukemia cell lines. Mean: mean of five experiments; SE: standard error. Comparison of the means of control with means of cells cultured with Andosan 10% showed a statistically significant difference ( p = 0.02).

    Article Snippet: The human leukemic cell lines KG1a, HL 60, and Meg 01 were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (German Collection of Microorganisms and Cell Cultures), Braunschweig, Germany.

    Techniques: Comparison, Control, Cell Culture